Cell and Gene Therapy Insights Volume 11 Issue 8

CELL AND GENE THERAPY INSIGHTS

Volume 11 Issue 8

Cell and Gene Therapy Insights Volume 11 Issue 8

Download PDF

Featuring

Issue Spotlight: Scale-up/-out of cell and gene therapy manufacturing
Other articles
Webinars

Scale-up/-out of cell and gene therapy manufacturing

Expert Insight

Tumor-infiltrating lymphocyte therapies: personal, powerful, with possibilities for improvement

Tumor-infiltrating lymphocyte therapies: personal, powerful, with possibilities for improvement

Sergio Ribeiro, Therese Choquette

Innovator Insight

Overcoming CMC hurdles in TIL therapy: strategic insights from a clinical-stage biotech

Overcoming CMC hurdles in TIL therapy: strategic insights from a clinical-stage biotech

Alex Lei, Sabrina Carmichael

AAV production and purification: key steps from design to GMP readiness

AAV production and purification: key steps from design to GMP readiness

G Ganjam, E Jackson-Holmes, F Leseigneur et al.

Commentary

People, not platforms: the real limit to cell and gene therapy scale-up in Europe

People, not platforms: the real limit to cell and gene therapy scale-up in Europe

A Miller, E Lombardo, J Kirby et al.

FastFacts

Temperature matters: fluid management for cell-based applications

Temperature matters: fluid management for cell-based applications

Jonathan Haider

Viewpoint

Scale-up and scale-out of extracellular vesicle production utilizing industrial grade bioreactors

Scale-up and scale-out of extracellular vesicle production utilizing industrial grade bioreactors

J Ene, F Syed, J Guan et al.

Bridging preclinical to commercial manufacturing in cell therapy: mind the gap

Bridging preclinical to commercial manufacturing in cell therapy: mind the gap

Ashwin Srinivasan Kumar, Sabry Hamza, Jaichandran Sivalingam

Time for the FDA and industry–academia partnerships to invest in fully automated, quality-controlled, scale-out of autologous cell and gene therapies

Time for the FDA and industry–academia partnerships to invest in fully automated, quality-controlled, scale-out of autologous cell and gene therapies

Avoiding slowdowns on the cell and gene therapy development pathway

Avoiding slowdowns on the cell and gene therapy development pathway

William E Janssen, Scott R Burger

Event Preview

Biologics CDMO Europe 2025

Biologics CDMO Europe 2025

Journal articles

Review

Autologous CAR-T cell immunotherapy for autoimmune diseases: a systematic review

Autologous CAR-T cell immunotherapy for autoimmune diseases: a systematic review

Tisha Singhal, John Maher

From bench to bedside: navigating bioanalytical method development and validation for clinical efficacy and regulatory compliance

From bench to bedside: navigating bioanalytical method development and validation for clinical efficacy and regulatory compliance

Innovator Insight

Modular iPSC workflow for allogeneic cell therapy applications: from iPSCs to iNKs

Modular iPSC workflow for allogeneic cell therapy applications: from iPSCs to iNKs

FastFacts

Deep phenotypic and cytotoxicity characterization of NK cells cultured with chemically defined additives

Deep phenotypic and cytotoxicity characterization of NK cells cultured with chemically defined additives

Poster

How do I get started with analytical assays? Top tips

How do I get started with analytical assays? Top tips

Interview

Perspectives on quality, compliance, and innovation to accelerate CGT manufacturing

Perspectives on quality, compliance, and innovation to accelerate CGT manufacturing

Bridging viral immunology and CAR-T therapy: leveraging natural T cell responses to enhance engineered cell therapies

Bridging viral immunology and CAR-T therapy: leveraging natural T cell responses to enhance engineered cell therapies

Catherine Bollard

Streamline disease modeling and therapeutic discovery with targeted viral vectors

Streamline disease modeling and therapeutic discovery with targeted viral vectors

Abhilasha Gupta

Dual CAR-T therapy targeting solid tumors: insights from intracerebroventricular delivery

Dual CAR-T therapy targeting solid tumors: insights from intracerebroventricular delivery

Stephen J. Bagley

Integrating microbubbles into a CAR-T workflow: more doses in a smaller footprint

Integrating microbubbles into a CAR-T workflow: more doses in a smaller footprint

Alex Sargent, Crisha Christensen

Achieving high yield and purity in lentiviral production using dPCR and IEX membranes

Achieving high yield and purity in lentiviral production using dPCR and IEX membranes

Jae Hwang, Oxana M Tsygankova

A framework for genomic integrity testing across the development lifecycle

A framework for genomic integrity testing across the development lifecycle

Prithy Martis, Erin Cross

Automating iPSC culture: scalable workflows

Automating iPSC culture: scalable workflows

Sophia Borate, Nathan Frank

Unlock advanced strategies in cell therapy analytics

Unlock advanced strategies in cell therapy analytics

S Peterson, K Shum, A Chandran et al.

De-risking Phase I/II trials for emerging biotech innovators

De-risking Phase I/II trials for emerging biotech innovators

J Gordon, L Timmerman, D Schaumberg et al.

A more perfect disease model – engineered iPSCs from innovation to discovery

A more perfect disease model – engineered iPSCs from innovation to discovery

Oscar Perez, Chris Heger

Managing raw material changes in cell & gene therapy: ensuring compliance and consistency

Managing raw material changes in cell & gene therapy: ensuring compliance and consistency

J King-Hart, M Mendicino, K Kime et al.

Enabling scalable CAR-T therapies with next-gen animal component-free T cell media

Enabling scalable CAR-T therapies with next-gen animal component-free T cell media

Pedro Azevedo Da Silva Couto, Rukmini Ladi

Non-viral, large-scale delivery of gene editing tools for T cell manufacturing

Non-viral, large-scale delivery of gene editing tools for T cell manufacturing

Stefanie Müthel, Andrea Toell

Avoiding the pitfalls: 5 lessons for cell therapy manufacturing success

Avoiding the pitfalls: 5 lessons for cell therapy manufacturing success

Joseph Garrity

Automating autologous CAR T manufacturing: Timing, technology transfer and the future of operational efficiency

Automating autologous CAR T manufacturing: Timing, technology transfer and the future of operational efficiency

M Hewitt, M Parvizi, E Stone